An Indiana man has filed a Xarelto lawsuit alleging Janssen Pharmaceutica’s popular blood thinner caused him to experience severe bleeding. The new Xarelto lawsuit will join hundreds of similar cases centralized late last year in the U.S. District Court for the Eastern District of Louisiana.
Xarelto was approved by the U.S. Food and Drug Administration in 2011 to help prevent blood clotting in patients who have undergone surgery or have an irregular heart rate. Over the past four years, Xarelto has risen to be the top-selling blood thinner of its type, with more than 11 million prescriptions in the United States. Despite its impressive sales record, however, Xarelto has found itself at the center of extensive litigation. Plaintiffs in Xarelto lawsuits claim the drug’s manufacturers, including Janssen Pharmaceutica and Bayer, released their drug without adequate premarket testing, and downplayed or concealed information about Xarelto’s side effects.
Xarelto lawsuits are backed up by medical evidence in the form of adverse event reports and research studies, one of which recently linked the anticoagulant to eye bleeding. In December 2014, Xarelto lawsuits reached a critical mass, with the U.S. Panel on Muldistrict Litigation deciding to centralize them in federal court in Louisiana. In the months since then, the number of Xarelto lawsuits in the multidistrict litigation has more than quadrupled.
Consult your doctor before switching or suspending any medications. If you or someone you know experienced severe bleeding or otherwise suffered after taking Xarelto, contact the pharmaceutical lawyers at Lopez McHugh today for a free legal consultation. We can help determine whether a Xarelto lawsuit is right for you.
